Skip to content

THE TEMSTEM TRIAL: Reducing distress and dysfunction caused by auditory verbal hallucinations via a smartphone application.

THE TEMSTEM TRIAL: Reducing distress and dysfunction caused by auditory verbal hallucinations via a smartphone application. - TEMSTEM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45092
Enrollment
100
Registered
2015-12-22
Start date
2016-03-23
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hallucinations voice hearing

Interventions

*Temstem + AVHs monitoring* will be compared with *AVH monitoring only*. In the AVH monitoring only condition participants will daily monitor their AVHs in a 30 second assessment. In the temstem + A

Sponsors

Vrije Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Presence of AVHs (with distress) for longer than a month * Presence of AVHs during a minimum of four days a week, in at least three of the last four weeks

Exclusion criteria

Exclusion criteria: * Changes in medication regiment in the last month * Estimated IQ under 70; the researchers will examine the schoolcareer of the patient. If problems during the primaryschool period are found, the short version of the WAIS-IV will be conducted to determine intelligence. * Insufficient competence in the Dutch language * Previous use of temstem * Not willing or able to learn to use a smartphone * Currently undergoing cognitive behavioural therapy for AVHs * Current involuntary admission in a closed ward

Design outcomes

Primary

MeasureTime frame
The primary outcomes are changes in distress, disturbance to life and social dysfunction caused by AVHs.

Secondary

MeasureTime frame
Changes in frequency and severity of AVHs; control and power over AVHs; ability to cope with AVHs; self-esteem; depression; quality of life; paranoid ideations.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)